12月12日，港通医疗发布公告，聘任夏沧澜先生为公司副总经理。 资料显示，夏沧澜先生，中国国籍，无境外永久居留权，1981年出生，博士研究生学历，正高级经济 师。曾任上海宏联工贸有限公司加贝分公司销售代表；中达电通股份有限公司产品维修工程师、技术支 持工程师、成都产品维修处经理；菲律宾SCJohnson客服代表、储备经理；成都华气厚普机电设备股份 有限公司总经理助理、人力资源总监、LNG成套设备中心副总经理、副总经理、董事；青岛诺安机电 科技有限公司总经理；成都海科机械设备制造有限公司总经理；中际联合(北京)科技股份有限公司供应 链管理中心总经理；深圳市万德数字科技有限公司总经理。 四川港通医疗设备集团股份有限公司（股票代码：301515）是一家现代化的医疗器械研发制造及智慧医 疗专业系统整体方案提供商，致力于解决医用气体供应及医疗感染问题，为各类医疗机构提供安全、稳 定、高效、智能的生命支持系统和生命支持区域，主营业务为医用气体装备及系统、医用洁净装备及系 统的研发、设计、制造、集成及运维服务。2023年7月25日，港通医疗在深交所创业板成功挂牌。 近三年董事和高级管理人员薪酬方面，港通医疗2022年高管薪 ...

Core Viewpoint - The Shenzhen-Hong Kong Stock Connect Medical Index (港币) closed at 4287.1 points, down 0.23%, with a trading volume of 7.011 billion yuan and a turnover rate of 0.72% [1] Group 1: Index Performance - On the day, 18 constituent stocks rose, with Blue Sail Medical leading with a 10.0% increase, while 36 stocks declined, with Yimai Sunshine leading the decline at 3.83% [1] - The net outflow of main funds from the Shenzhen-Hong Kong Stock Connect Medical Index constituents totaled 115 million yuan, while retail investors saw a net inflow of 181 million yuan [1] Group 2: Constituent Stocks Details - The top ten constituent stocks of the Shenzhen-Hong Kong Stock Connect Medical Index include: - Yimai Sunshine (hk02522) with a market cap of 3.43 billion yuan and a price drop of 3.83% [1] - Weikang Medical (hk00853) with a market cap of 17.4 billion yuan and a price drop of 3.38% [1] - Weikang Robotics (hk02252) with a market cap of 19.21 billion yuan and a price drop of 2.84% [1] - Wu Hai Biotechnology (hk06826) with a market cap of 5.46 billion yuan and a price drop of 2.27% [1] - Dian Diagnostics (sz300244) with a market cap of 9.19 billion yuan and a price drop of 2.13% [1] - Ruimaite (sz301367) with a market cap of 7.59 billion yuan and a price drop of 2.08% [1] - Tuya Holdings (hk01099) with a market cap of 56.54 billion yuan and a price drop of 1.96% [1] - Yidu Technology (hk02158) with a market cap of 4.83 billion yuan and a price drop of 1.96% [1] - Xintai Medical (hk02291) with a market cap of 5.23 billion yuan and a price drop of 1.83% [1] - Chunli Medical (hk01858) with a market cap of 5.26 billion yuan and a price drop of 1.76% [1]

截至2025年12月12日收盘，港通医疗（301515）报收于19.84元，较前一交易日下跌2.02%，最新总市值 为19.84亿元。该股当日开盘20.26元，最高20.48元，最低18.0元，成交额达3525.03万元，换手率为 2.68%。 同日，港通医疗发布公告称，公司于2025年12月12日召开第五届董事会第七次会议，审议通过聘任夏沧 澜先生为公司副总经理的议案。公告显示，夏沧澜先生具备相关法律法规和公司章程规定的任职资格， 未持有公司股份，与公司实际控制人、其他董事、高级管理人员及持股5%以上股东无关联关系。其任 期自董事会审议通过之日起至第五届董事会任期届满为止。 最新公告列表 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 《关于聘任公司副总经理的公告》 《第五届董事会第七次会议决议公告》 ...

证券日报网讯 12月12日晚间，港通医疗发布公告称，公司第五届董事会第七次会议于2025年12月12日 召开，审议通过了《关于聘任公司副总经理的议案》，同意聘任夏沧澜先生为公司副总经理，任期自第 五届董事会第七次会议审议通过之日起至第五届董事会任期届满之日止。 （文章来源：证券日报） ...

Core Points - The Shenzhen-Hong Kong Stock Connect Medical Index (HKD) closed at 4302.26 points, up 1.09% with a trading volume of 10.694 billion HKD and a turnover rate of 1.0% [1] - Among the constituent stocks, 39 stocks rose, with Baize Medical leading with a 5.14% increase, while 16 stocks fell, with Furuide leading the decline at 3.23% [1] Fund Flow Analysis - The total net inflow of main funds into the Shenzhen-Hong Kong Stock Connect Medical Index constituents was 80.9503 million HKD, while speculative funds saw a net outflow of 283 million HKD, and retail investors had a net inflow of 202 million HKD [2]

Core Points - The Shenzhen-Hong Kong Medical Index (983035) closed at 4383.23 points, up 0.98% with a trading volume of 9.693 billion yuan and a turnover rate of 1.0% [1] - Among the constituent stocks, 39 stocks rose, with Baize Medical leading with a 5.14% increase, while 16 stocks fell, with Furuide leading the decline at 3.23% [1] - The net inflow of main funds into the Shenzhen-Hong Kong Medical Index constituents totaled 80.9503 million yuan, while speculative funds saw a net outflow of 283 million yuan, and retail investors had a net inflow of 202 million yuan [2] Group 1 - The Shenzhen-Hong Kong Medical Index reported a positive performance with a 0.98% increase [1] - Baize Medical showed the highest gain among constituents with a 5.14% rise [1] - Furuide experienced the largest decline with a 3.23% drop [1] Group 2 - The total net inflow of main funds was 80.9503 million yuan [2] - Speculative funds experienced a significant net outflow of 283 million yuan [2] - Retail investors contributed to a net inflow of 202 million yuan [2]

Group 1 - Shouyao Holdings is planning to issue H-shares and list on the Hong Kong Stock Exchange, with discussions ongoing with intermediaries regarding the specifics of the listing [1] - Jiangsu Guoxin's subsidiary, Guoxin Mazhou, has completed the trial operation of a 1000MW coal-fired power unit, which is set to officially commence operations on December 12, 2025 [2] - Yuekang Pharmaceutical's mRNA tumor vaccine has received clinical trial approval from the National Medical Products Administration for treating advanced solid tumors [3] Group 2 - Dongli New Science plans to invest 666 million yuan in the restructuring of SAIC Hongyan, acquiring approximately 14.66% equity post-restructuring [4] - Longsheng Technology is set to invest approximately 350 million yuan in the establishment of an intelligent robot innovation center in Wuxi [5] - Shangwei Co. has received a government subsidy of 2.212 million yuan, which accounts for 13.53% of its audited net profit for 2024 [6] Group 3 - Anglikang has received drug registration certificates for Diclofenac Sodium Enteric-Coated Tablets and approval for a supplemental application for Sacubitril/Valsartan Sodium Tablets [7] - Guangzhou Development has received acceptance notices for the registration of 8 billion yuan in medium-term notes and 6 billion yuan in short-term financing bonds [8] - Kebo Da plans to increase capital by 21.2 million euros (approximately 174 million yuan) in its wholly-owned subsidiary in Germany [9][10] Group 4 - Changguang Huaxin has received a total of 11.6672 million yuan in government subsidies, including 8.0552 million yuan related to income [11] - Haizheng Pharmaceutical's subsidiary has received a European Pharmacopoeia suitability certificate for its raw material [12] - Qianjin Pharmaceutical's subsidiary has received a drug registration certificate for Lurasidone Hydrochloride Tablets, used for treating schizophrenia [13] Group 5 - Daimai Co. has received a warning letter from the Shanghai Securities Regulatory Bureau due to failure to timely disclose a significant event related to a fire incident [14] - ST Changyao's subsidiary has recently ceased production due to financial difficulties and competitive pressures in the photovoltaic industry [15] - Guodian Power is investing in the construction of a 2×1000MW expansion project at the Ganbi Power Plant, with a total dynamic investment of 7.218 billion yuan [16] Group 6 - Kaichuang International's subsidiary has completed the handover of a tuna purse seine vessel, expected to be operational by 2026 [16] - Tieke Rail plans to sign an energy management agreement for a distributed photovoltaic project, which is expected to save approximately 1.441 million yuan in electricity costs over 25 years [18] - Bailian Co. plans to sign a land compensation agreement with Friendship Logistics, with a total compensation of 103 million yuan [19] Group 7 - Dayu Water-saving's subsidiary has been pre-awarded two high-standard farmland construction projects, with total expected amounts of 137 million yuan and 135 million yuan respectively [20] - Tianma Technology reported a total eel output of approximately 1197.15 tons in November, with sales prices ranging from 53,000 yuan/ton to 89,000 yuan/ton [21] - Guorui Technology's subsidiary has been shortlisted for the GXLF project with a bid of 76 million yuan [22] Group 8 - Qingdao Food's deputy general manager has resigned for personal reasons [23] - Guosheng Zhike plans to use up to 900 million yuan of idle funds for cash management [24] - Guodian Nanrui plans to use up to 23 billion yuan of idle funds for entrusted wealth management [25] Group 9 - Jiahuan Energy plans to merge its wholly-owned subsidiary, Zhejiang Jiahuan Hydrogen Peroxide Co., Ltd., through an overall absorption merger [26] - Ganyue Expressway reported vehicle toll service revenue of 309 million yuan for November [27] - Jinling Hotel's chairman has resigned due to work changes [28] Group 10 - Lisheng Pharmaceutical's subsidiary has received drug registration certificates for Apremilast Tablets [29] - Baotai has received a positive opinion from the European Medicines Agency for Gotenfia® for various inflammatory conditions [30] - ST Zhisheng has been awarded a smart city governance project with a bid amount of 104 million yuan [31] Group 11 - Chenxi Aviation and its related personnel have received administrative regulatory measures from the Shaanxi Securities Regulatory Bureau due to financial reporting issues [32] - Portong Medical has appointed Xia Canglan as the new deputy general manager [33] - Maide Medical plans to repurchase shares with a total amount between 20 million and 40 million yuan [34] Group 12 - Jimin Health plans to establish a joint venture with a total investment of 600 million yuan, focusing on AI and software development [35] - Beilu Pharmaceutical has received a drug registration certificate for Pioglitazone Metformin Tablets [36] - Hainan Mining plans to entrust the overall management of the Shiluo Iron Mine to a construction company for three years, with a total contract amount of approximately 818 million yuan [38] Group 13 - Huiyu Pharmaceutical has received a drug registration certificate for Nicardipine Hydrochloride Injection [39] - Baoland has received a government subsidy of 10 million yuan related to income [40] - Qingdao Port has terminated the acquisition of 100% equity in an oil company and 50% equity in Rizhao Shihua due to regulatory concerns [41]

每经AI快讯，港通医疗12月12日晚间发布公告称，公司第五届第七次董事会会议于2025年12月12日在 公司会议室以现场结合通讯的方式召开。会议审议了《关于聘任公司副总经理的议案》等文件。 每经头条（nbdtoutiao）——专访管涛：美国政府经济贸易政策正逐渐动摇美元本位国际货币体系，利 多因素下人民币汇率有可能破7 （记者 贾运可） 免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 ...

证券之星消息，港通医疗(301515)12月12日在投资者关系平台上答复投资者关心的问题。 投资者提问：您好，请问截止2025年12月10日，公司股东数是多少？ 港通医疗回复：尊敬的投资者，您好！公司截至2025年12月10日股东总户数为7355户，感谢您的关注。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...

Company Announcement - The company, 港通医疗, announced the appointment of Mr. 夏沧澜 as the new Vice President [1] Revenue Composition - For the first half of 2025, the revenue composition of 港通医疗 is as follows: - Medical clean equipment and systems account for 55.69% - Medical gas equipment and systems account for 37.3% - Sales of medical devices and other products account for 4.06% - Operation and maintenance services account for 2.81% - Other businesses account for 0.14% [1] Market Capitalization - As of the report, 港通医疗 has a market capitalization of 2 billion yuan [1]